Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes

Blood

Volumn 97, Issue 11, 2001, Pages 3531-3536

  Braun, Michael C ^a,b,c   Wang, Ji Ming ^a,b,c   Lahey, Edward ^a,b,c   Rabin, Ronald L ^a,b,c   Kelsall, Brian L ^a,b,c  

^a Mucosal Immunity Section   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; N FORMYL PEPTIDE RECEPTOR; PROTEIN; PROTEIN P70; RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOREGULATION; MONOCYTE; PRIORITY JOURNAL; TH1 CELL;

EID: 0035383774     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3531     Document Type: Article

References (54)

1. + cell numbers and clinical staging. J Clin Invest. 1989; 84:1892-1899.
2. Gruters RA, Terpstra FG, De Jong R, Van Noesel CJ, Van Lier RA, Miedema F. Selective loss of T cell functions in different stages of HIV infection: early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in Al DS-related complex and AIDS. Eur J Immunol. 1990;20: 1039-1044.
3. + T helper cell depletion occurs. J Clin Invest. 1988;82:1908-1914.
4. Khoo SH, Wilkins EG, Fraser IS, Hamour AA, Stanford JL. Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts. Thorax. 1996;51:932-935.
5. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells [see comments]. Science. 1994;265:244-248.
6. Nicastri E, Sarmati L, Ercoli L, et al. Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects [In Process Citation]. AIDS. 1999;13:1333- 1336.
7. Ballet JJ, Couderc LJ, Rabian-Herzog C, et al. Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. AIDS. 1988;2:291-297.
8. Chougnet C, Wynn TA, Clerici M, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis. 1996;174:46-53.
9. Chehimi J, Starr SE, Frank I, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med. 1994;179: 1361-1366.
10. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 1997;11:1111-1118.
11. Hardson TS, Levitz SM. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection. J Immunol. 1996;156:4492-4497.
12. Gazzinelli RT, Bala S, Stevens R, et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J Immunol. 1995;155:1565-1574.
13. Meyaard L, Hovenkamp E, Pakker N, van der Pouw Kraan TC, Miedema F. Interleukin-12 (IL-12) production in whole blood cultures from human immunodeficiency virus-infected individuals studied in relation to IL-10 and prostaglandin E2 production. Blood. 1997;89:570-576.
14. Marshall JD, Chehimi J, Gri G, Kostman JR, Montaner LJ, Trinchieri G. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Blood. 1999;94:1003-1011.
15. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177: 898-904.
16. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998;12:F123-F129.
17. Clerici M, Seminari E, Suter F, et al. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia: the Master Group. AIDS. 2000;14:109-116.
18. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science. 1993; 262:1721-1724.
19. Landay AL, Clerici M, Hashemi F, Kessler H, Berzofsky JA, Shearer GM. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis. 1996;173: 1085-1091.
20. Foli A, Savilie MW, Baseler MW, Yarchoan R. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood. 1995;85: 2114-2123.
21. Newman GW, Guarnaccia JR, Vance EA III, Wu JY, Remold HG, Kazanjian PH Jr. Inteleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to Mycobacterium avium. AIDS. 1994;8:1413-1419.
22. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol. 1998;160:3194-3206.
23. + T cells, modulated by cytokines and effected by lymphotoxin. AIDS. 1996; 10:603-611.
24. + T cells from human immunodeficiency virus-infected persons. J Exp Med. 1995; 182:1759-1767.
25. Clerici M, Sarin A, Coffman RL, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A. 1994;91:11811-11815.
26. Su SB, Gong WH, Gao JL, et al. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood. 1999;93:3885-3892.
27. Deng X, Ueda H, Su SB, et al. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood. 1999;94:1165-1173.
28. Wild C, Dubay JW, Greenwell T, et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A. 1994;91:12676-12680.
29. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91:9770-9774.
30. Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr, Merutka G. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically active peptides from gp41. Biochemistry. 1996;35:13697-13708.
31. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion [letter]. AIDS Res Hum Retroviruses. 1993;9:1051-1053.
32. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments]. Nat Med. 1998;4:1302-1307.
33. Becker EL, Forouhar FA, Grunnet ML, et al. Broad immunocytochemical localization of the formyl peptide receptor in human organs, tissues, and cells. Cell Tissue Res. 1998;292:129-135.
34. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med. 1994; 180:253-260.
35. Su SB, Gong W, Gao JL, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999;189:395-402.
36. Zisman DA, Kunkel SL, Strieter RM, et al. MCP-1 protects mice in lethal endotoxemia. J Clin Invest. 1997;99:2832-2836.
37. Wittmann M, Zwirner J, Larsson VA, et al. C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol. 1999;162: 6763-6769.
38. Karpus WJ, Kennedy KJ, Kunkel SL, Lukacs NW. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines. J Exp Med. 1998;187:733-741.
39. Braun MC, Lahey E, Kelsall BL. Selective suppression of IL-12 production by chemoattractants. J Immunol. 2000;164:3009-3017.
40. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-135.
41. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol. 1999;162:3840-3850.
42. Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996;183: 147-157.
43. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998;160: 5936-5944.
44. + T cells and proinflammatory Th-1-type cytokines. J Immunol. 1997; 158:1068-1077.
45. He J, Gurunathan S, Iwasaki A, Ash-Shaheed B, Kelsall BL. Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses. J Exp Med. 2000;191:1605-1610.
46. Kamradt T, Soloway PD, Perkins DL, Gefter ML. Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein. J Immunol. 1991;147:3296-3302.
47. Ito M, Ishida T, He L, et al. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 1998;14:845-849.
48. Albini A, Ferrini S, Benelli R, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A. 1998;95:13153-13158.
49. Chougnet C, Cohen SS, Kawamura T, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol. 1999;163: 1666-1673.
50. Konecny P, Stagg AJ, Jebbari H, English N, Davidson RN, Knight SC. Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol. 1999;29: 1803-1811.
51. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998;28:687-695.
52. Su SB, Gao J, Gong W, et al. T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J Immunol. 1999;162:5924-5930.
53. Adamson DC, McArthur JC, Dawson TM, Dawson VL. Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Mol Med. 1999;5:98-109.
54. Chad DA, Smith TW, Blumenfeld A, Fairchild PG, DeGirolami U. Human immunodeficiency virus (HIV)-associated myopathy: immunocytochemical identification of an HIV antigen (gp 41) in muscle macrophages. Ann Neurol. 1990;28:579-582.